myNEO Therapeutics develops breakthrough immunotherapies by leveraging the ImmunoEngine platform to identify novel tumor targets called camyotopes from the dark genome. These targets offer the potential to expand immunotherapy efficacy to patient populations currently unresponsive to existing treatments. The company focuses on creating data-driven precision cancer therapies using these unique, cancer-specific targets.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancer patients do not respond to existing immunotherapies due to a lack of identifiable and targetable tumor antigens. The limitations in current antigen discovery methods hinder the development of effective personalized cancer treatments.
Solution
myNEO Therapeutics leverages its ImmunoEngine platform to identify camyotopes, a novel class of tumor antigens derived from the dark genome, to enhance immunotherapy effectiveness. The ImmunoEngine platform utilizes whole-genome sequencing data from patient blood and tumor biopsies, employing a suite of algorithms called 'neoX' to detect somatic gene alterations. These alterations are then translated in-silico into tumor-specific peptides, which are prioritized using immunogenicity (neoIM) and presentation predictors (neoMS and MHCrank). This approach enables the discovery of more and better targets, unlocking first-in-class targets from the under-exploited dark genome.
Target Audience
The primary customers are biopharmaceutical companies and clinical researchers focused on developing novel immunotherapies and personalized cancer treatments.
Features
- ImmunoEngine platform for antigen discovery, tapping into novel tumor targets found in the dark genome (camyotopes)
- neoX algorithms for detecting somatic gene alterations from whole-genome sequencing data
- In-silico translation of somatic gene alterations to obtain tumor-specific peptides
- Prioritization of peptides using immunogenicity predictor (neoIM) and presentation predictors (neoMS and MHCrank)
- Identification of camyotopes that display specific translation only in cancer cells, limiting off-target toxicity
- Camyotopes with very high abundance within patients, de-risking immune escape
- Target discovery services including screening omics databases and patient biopsies, matching tumor antigen targets with population of interest, and differential expression analysis
- Pre-clinical services including construct design, coordination of pre-clinical validation experiments, and mechanism of action analysis
- Clinical services including deep investigation of patient data, biomarker identification, and therapy response prediction